David E. Griffith

21.0k total citations · 3 hit papers
173 papers, 12.2k citations indexed

About

David E. Griffith is a scholar working on Epidemiology, Infectious Diseases and Small Animals. According to data from OpenAlex, David E. Griffith has authored 173 papers receiving a total of 12.2k indexed citations (citations by other indexed papers that have themselves been cited), including 129 papers in Epidemiology, 94 papers in Infectious Diseases and 46 papers in Small Animals. Recurrent topics in David E. Griffith's work include Mycobacterium research and diagnosis (116 papers), Tuberculosis Research and Epidemiology (90 papers) and Infectious Diseases and Mycology (45 papers). David E. Griffith is often cited by papers focused on Mycobacterium research and diagnosis (116 papers), Tuberculosis Research and Epidemiology (90 papers) and Infectious Diseases and Mycology (45 papers). David E. Griffith collaborates with scholars based in United States, Netherlands and Canada. David E. Griffith's co-authors include Richard J. Wallace, Barbara A. Brown‐Elliott, Charles L. Daley, Timothy R. Aksamit, Barbara A. Brown, Kevin Winthrop, Kenneth N. Olivier, Stephen J. Ruoss, Antonino Catanzaro and C. Fordham von Reyn and has published in prestigious journals such as The Journal of Immunology, PLoS ONE and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

David E. Griffith

167 papers receiving 11.8k citations

Hit Papers

An Official ATS/IDSA Statement: Diagnosis, Treatm... 1993 2026 2004 2015 2007 1993 2016 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases
    2007 4.3k citations David E. Griffith, Timothy R. Aksamit et al. American Journal of Respiratory and Critical Care Medicine profile →
  2. Clinical Features of Pulmonary Disease Caused by Rapidly Growing Mycobacteria: An Analysis of 154 Patients
    1993 410 citations David E. Griffith, William M. Girard et al. profile →
  3. Adult Patients With Bronchiectasis
    2016 251 citations Timothy R. Aksamit, Anne E. O’Donnell et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David E. Griffith United States 53 10.0k 7.2k 4.7k 1.8k 1.8k 173 12.2k
Kenneth N. Olivier United States 48 9.3k 0.9× 6.2k 0.9× 4.3k 0.9× 1.7k 1.0× 3.0k 1.7× 148 12.5k
Won‐Jung Koh South Korea 56 8.3k 0.8× 6.8k 0.9× 3.6k 0.8× 2.2k 1.2× 2.1k 1.2× 352 11.1k
Antonino Catanzaro United States 38 8.3k 0.8× 7.1k 1.0× 2.4k 0.5× 1.9k 1.0× 1.1k 0.6× 138 10.6k
Michael D. Iseman United States 35 7.0k 0.7× 5.8k 0.8× 2.4k 0.5× 2.4k 1.3× 1.1k 0.6× 72 9.3k
Jakko van Ingen Netherlands 52 7.0k 0.7× 5.8k 0.8× 2.8k 0.6× 1.3k 0.7× 470 0.3× 247 8.4k
Stephen J. Ruoss United States 29 4.8k 0.5× 3.4k 0.5× 2.3k 0.5× 1.4k 0.8× 1.2k 0.7× 63 7.2k
Timothy R. Aksamit United States 29 5.4k 0.5× 3.7k 0.5× 2.4k 0.5× 1.2k 0.7× 1.6k 0.9× 90 6.9k
Gwen A. Huitt United States 22 5.7k 0.6× 4.0k 0.5× 2.9k 0.6× 1.2k 0.7× 718 0.4× 30 6.4k
Shahid Husain Canada 54 6.6k 0.7× 5.2k 0.7× 633 0.1× 2.3k 1.3× 806 0.5× 250 10.4k
Li‐Na Lee Taiwan 45 2.9k 0.3× 2.4k 0.3× 530 0.1× 1.4k 0.8× 1.4k 0.8× 187 5.5k

Countries citing papers authored by David E. Griffith

Since Specialization
Citations

This map shows the geographic impact of David E. Griffith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David E. Griffith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David E. Griffith more than expected).

Fields of papers citing papers by David E. Griffith

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David E. Griffith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David E. Griffith. The network helps show where David E. Griffith may publish in the future.

Co-authorship network of co-authors of David E. Griffith

This figure shows the co-authorship network connecting the top 25 collaborators of David E. Griffith. A scholar is included among the top collaborators of David E. Griffith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David E. Griffith. David E. Griffith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ali, Farihah, Cayley Russell, Sameer Imtiaz, et al.. (2025). Characterizing changes to harm reduction site operations in British Columbia following the implementation of the decriminalization of drugs: Findings from a provincial survey. Harm Reduction Journal. 22(1). 122–122. 1 indexed citations
2.
Morimoto, Kozo, Jack R. Gallagher, Dirk Wagner, David E. Griffith, & Jakko van Ingen. (2024). Real-World Patients’ Diagnosis-to-Treatment Journey with Nontuberculous Mycobacterial Pulmonary Disease: A Cross-Sectional Survey. Infectious Diseases and Therapy. 13(8). 1907–1920. 3 indexed citations
3.
Bai, Xiyuan, Jun‐Feng Gao, David E. Griffith, et al.. (2024). Analysis of alpha‐1‐antitrypsin (AAT)‐regulated, glucocorticoid receptor‐dependent genes in macrophages reveals a novel host defense function of AAT. Physiological Reports. 12(14). e16124–e16124. 1 indexed citations
4.
Nguyen, Minh-Vu H, Michelle Haas, Shannon Kasperbauer, et al.. (2024). Nontuberculous Mycobacterial Pulmonary Disease: Patients, Principles, and Prospects. Clinical Infectious Diseases. 79(4). e27–e47. 11 indexed citations
5.
Lyu, Jiwon, Susan L. Baldwin, Sasha E. Larsen, et al.. (2024). Understanding the development of tuberculous granulomas: insights into host protection and pathogenesis, a review in humans and animals. Frontiers in Immunology. 15. 1427559–1427559. 6 indexed citations
6.
Schildkraut, Jodie A., Jack R. Gallagher, Kozo Morimoto, et al.. (2020). Epidemiology of nontuberculous mycobacterial pulmonary disease in Europe and Japan by Delphi estimation. Respiratory Medicine. 173. 106164–106164. 28 indexed citations
7.
Winthrop, Kevin, Patrick A. Flume, Rachel Thomson, et al.. (2020). Amikacin Liposome Inhalation Suspension for Mycobacterium avium Complex Lung Disease: A 12-Month Open-Label Extension Clinical Trial. Annals of the American Thoracic Society. 18(7). 1147–1157. 46 indexed citations
8.
Griffith, David E., Gina Eagle, Rachel Thomson, et al.. (2018). Randomized Phase 3 Trial of Amikacin Liposome Inhalation Suspension (ALIS) for Treatment-Refractory Nontuberculous Mycobacterial (NTM) Lung Disease Caused by Mycobacterium Avium Complex (MAC) in Adult Patients. American Journal of Respiratory and Critical Care Medicine. 197. 1 indexed citations
9.
Winthrop, Kevin, Gina Eagle, Rachel Thomson, et al.. (2018). Six-Minute Walk Test (6MWT) Performance in Adult Patients Receiving Amikacin Liposome Inhalation Suspension (ALIS) for Treatment-Refractory Nontuberculous Mycobacterial (NTM) Lung Disease Caused by Mycobacterium Avium Complex (MAC). American Journal of Respiratory and Critical Care Medicine. 197.
10.
Seaworth, Barbara & David E. Griffith. (2017). Therapy of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. Microbiology Spectrum. 5(2). 35 indexed citations
11.
Alexander, David C., Ravikiran Vasireddy, Sruthi Vasireddy, et al.. (2016). Emergence of mmpT5 Variants during Bedaquiline Treatment of Mycobacterium intracellulare Lung Disease. Journal of Clinical Microbiology. 55(2). 574–584. 65 indexed citations
12.
Olivier, Kenneth N., David E. Griffith, Gina Eagle, et al.. (2016). Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease. American Journal of Respiratory and Critical Care Medicine. 195(6). 814–823. 169 indexed citations
13.
Krupa, Agnieszka, Marek Fol, Bożena Dziadek, et al.. (2015). Binding of CXCL8/IL‐8 to Mycobacterium tuberculosis Modulates the Innate Immune Response. Mediators of Inflammation. 2015(1). 124762–124762. 63 indexed citations
14.
Garg, Ankita, Peter F. Barnes, Angel Porgador, et al.. (2006). Vimentin Expressed on Mycobacterium tuberculosis -Infected Human Monocytes Is Involved in Binding to the NKp46 Receptor. The Journal of Immunology. 177(9). 6192–6198. 144 indexed citations
15.
Griffith, David E., Barbara A. Brown‐Elliott, Sara Shepherd, et al.. (2005). Ethambutol Ocular Toxicity in Treatment Regimens for Mycobacterium avium Complex Lung Disease. American Journal of Respiratory and Critical Care Medicine. 172(2). 250–253. 77 indexed citations
16.
Wallace, Richard J., Yansheng Zhang, Barbara A. Brown, et al.. (1998). Polyclonal Mycobacterium avium Complex Infections in Patients with Nodular Bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 158(4). 1235–1244. 131 indexed citations
17.
Brown, Barbara A., et al.. (1996). Clarithromycin Regimens for Pulmonary Mycobacterium Avium Complex. The First 50 Patients. American Journal of Respiratory and Critical Care Medicine. 153(6). 1766–1772. 203 indexed citations
18.
Griffith, David E., et al.. (1995). Tuberculosis Outbreak Among Healthcare Workers in a Community Hospital. American Journal of Respiratory and Critical Care Medicine. 152(2). 808–811. 53 indexed citations
19.
Wallace, Richard J., Barbara A. Brown, David E. Griffith, et al.. (1994). Initial Clarithromycin Monotherapy for Mycobacterium Avium-Intracellulare Complex Lung Disease. American Journal of Respiratory and Critical Care Medicine. 149(5). 1335–1341. 143 indexed citations
20.
Griffith, David E. & Gerald H. Mazurek. (1991). Pneumonia in Chronic Obstructive Lung Disease. Infectious Disease Clinics of North America. 5(3). 467–484. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kenneth N. Olivier Breakdown of academic impact, for papers by Won‐Jung Koh Breakdown of academic impact, for papers by Antonino Catanzaro Breakdown of academic impact, for papers by Michael D. Iseman Breakdown of academic impact, for papers by Jakko van Ingen Breakdown of academic impact, for papers by Stephen J. Ruoss Breakdown of academic impact, for papers by Timothy R. Aksamit Breakdown of academic impact, for papers by Gwen A. Huitt Breakdown of academic impact, for papers by Shahid Husain Breakdown of academic impact, for papers by Li‐Na Lee
Rankless by CCL
2026